UNSPSC 51184012: Glisoxepid or glisoxepide

This classification denotes an anti-diabetic agent with the molecular formula C20H27N5O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H7SC0I332I, chemically known as 3-isoxazolecarboxamide, n-(2-(4-(((((hexahydro-1h-azepin-1-yl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl- but more generally known as glisoxepid, which bears US NIH Compound Identifier 32778. European Medicines Agency schedules Glisoxepide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07933MIG.

UNSPSC 51184012 Glisoxepid or glisoxepide is a Commodity code covering specific pharmaceutical active ingredients supplied through cooperative purchasing agreements to state and local government healthcare facilities. State and local governments buy this ingredient as part of broader generic multi-source pharmaceutical procurement programs administered through multistate cooperative purchasing alliances rather than as standalone commodity purchases. The issuing bodies for this code span state health and human services departments, correctional facilities, state hospitals, and participating local government health agencies coordinated through cooperative purchasing vehicles like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Vendors responding to opportunities under this code must comply with cGMP and Drug Supply Chain Security Act requirements, maintain relationships with FDA-authorized wholesalers, carry substantial insurance coverage ($5 million general liability, $2 million network security and privacy liability, $2 million professional liability), and accept 3 percent administrative fees plus performance-based penalties for reporting or onboarding failures.

The Minnesota Department of Administration's Office of State Procurement issued the most recent relevant opportunity: MMCAP's Request for Proposal S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with a response deadline of March 26, 2026. The RFP established multiple contracts effective July 1, 2026, for a two-year term with optional extensions, requiring vendors to distribute products through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC) across Minnesota, Oregon, and other participating jurisdictions. Evaluation weighted price competitiveness at 75 percent, with the remaining 25 percent divided among fixed pricing (10 percent), compliance with administrative data formats (5 percent), EDI capability (5 percent), and agreement to administrative fee structures (5 percent). No specific dollar values or set-aside designations were disclosed in the available documentation.